Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis

Kanis J (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK

Kanis JA et al (2008) FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19(4):385–397

Kanis JA et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18(8):1033–1046

Fujiwara S et al (2008) Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 19(4):429–435

Association Suisse contre l‘Osteoporose (2011) Osteoporose: Recommandations 2010. Bern

Neuprez A et al (2009) A FRAX model for the assessment of fracture probability in Belgium. Rev Med Liege 64(12):612–619

Grossman JM et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62:15–26

NOF (2008) Physician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DC

Socialstyrelsen (2010) Nationella riktlinjer för rörelseorganens sjukdomar 2012. Osteoporos, artros, inflammatorisk ryggsjukdom och ankyloserande spondylit, psoriasisartrit och reumatoid artrit. Stöd för styrning och ledning. 1-116. Publicerad

Papaioannou A et al (2010) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Cmaj 182(17):1864–1873

U.S. Preventive Services Task Force (2011) Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 154(5):356–364

Kanis JA et al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19(4):399–428

Kurth AA, Pfeilschifter J (2007) Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German Guidelines Update 2006. Orthopade 36(7):683–690, quiz 691

Compston J et al (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62(2):105–108

National Osteoporosis Foundation (2008) Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DC

National Institute for Health and Clinical Excellence (2010) Final appraisal determination 160. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence, London

National Institute for Health and Clinical Excellence (2010) Final appraisal determination 161. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence, London

National Institute for Health and Clinical Excellence (2010) Technology appraisals TA204: Osteoporotic fractures—denosumab. Accessed 5 June 2011; http://guidance.nice.org.uk/TA204

Kanis J et al (2010) An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Arch Osteoporos. doi: 10.1007/s11657-010-0045-5

Kanis JA et al (2008) Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. Osteoporos Int 19(10):1395–1408, Erratum published 2009 Osteoporos Int 20, 499–502

Borgstrom F et al (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21(3):495–505

Borgstrom F et al (2010) The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int 21(2):339–349

Cummings SR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765

Li L et al (2010) Non-persistence to anti-osteoporosis medications in the UK using the general practice research database (GPRD) Rheumatology 49 Supplement 1 (OP54)

Landfeldt E et al (2012) Adherence to treatment of primary osteoporosis and its association to fractures-the Swedish Adherence Register Analysis (SARA). Osteoporos Int 23(2):433–434

Jonsson B et al (2010) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22(3):967–982

Strom O et al (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20(1):23–34

NICE (2008) Guide to the methods of technology appraisal. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf . Accessed 18 Jan 2012

Strom O et al (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries—an economic evaluation based on the fracture intervention trial. Osteoporos Int 18(8):1047–1061

Kanis J et al (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6(29):1–146

Stevenson M et al (2005) A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess. 2005 Jun;9(22):1–160

Strom O et al (2010) FRAX and its applications in health economics—cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 47(2):430–437

Seeley DG et al (1991) Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. Ann Intern Med 115(11):837–842

National Institute for Health and Clinical Excellence (2008) Systematic reviews of clinical effectiveness prepared for the guideline osteoporosis: “assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk”. http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11621 . Accessed 12 March 2011

Freemantle N et al (2011) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23(1):317–326

Stevenson M, Davis S (2006) Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide. Accessed 13 May 2008; http://www.nice.org.uk/page.aspx?o=370643

Reginster JY et al (2009) Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone 45(6):1059–1064

Singer BR et al (1998) Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 80(2):243–248

de Lusignan S et al (2006) Using computers to identify non-compliant people at increased risk of osteoporotic fractures in general practice: a cross-sectional study. Osteoporos Int 17(12):1808–1814

Kanis JA et al (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11(7):iii–iv, ix-xi, 1–231

National Statistics: The official UK statistics site. www.statistics.gov.uk . Accessed 14 January 2011

Johnell O et al (2004) Mortality after osteoporotic fractures. Osteoporos Int 15(1):38–42

Stevenson M, Davis S, Kanis J (2006) The hospitalization costs and outpatient costs of fragility fractures. Women's Health Med 4:149–151

Kanis JA et al (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12(5):417–427

Borgstrom F et al (2006) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17(5):637–650

Ström O et al (2008) Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 79(2):269–280

Curtis L (2010) Unit Costs of Health and Social Care. http://www.pssru.ac.uk/pdf/uc/uc2010/uc2010.pdf . Accessed 1 Dec 2010

Jonsson B et al (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30–38

Swedish National Inpatient Register and Causes of Death Register, The Swedish National Board of Health Centre - The Epidemiological Centre, http://www.sos.se/epc/epceng.htm . Accessed 1 Dec 2011

Kanis JA et al (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15(2):108–112

Bliuc D et al (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. Jama 301(5):513–521

Kanis JA et al (2003) The components of excess mortality after hip fracture. Bone 32(5):468–473

Borgstrom F et al (2006) An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int 17(12):1781–1793

Kanis JA et al (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42(1):4–15

Kind P et al (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. Br Med J 316(7133):736–741

Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35(11):1095–1108

Stevenson M, Davis S (2006) Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide (NICE). The University of Sheffield, School of Health and Related Research, Sheffield

Borgstrom F et al (2004) Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. PharmacoEconomics 22(17):1153–1165

Kanis JA et al (2008) Case finding for the management of osteoporosis with FRAX((R))-assessment and intervention thresholds for the UK. Osteoporos Int 19(10):1395–1408

Cummings SR et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Jama 280(24):2077–2082

Scotland G et al (2011) Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. PharmacoEconomics 29(11):951–961

van Staa TP et al (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39(12):1383–1389

Kanis JA et al (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16(7):737–742

Kanis JA et al (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22(9):2395–2411

Delmas PD et al (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33(4):522–532

Klotzbuecher CM et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721–739

Kanis JA et al (2011) A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int

McCloskey EV et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20(5):811–817

Kanis JA et al (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44(6):1049–1054

McCloskey EV, Johansson H, Oden A, (2012) Denosumab reduces the risk of all osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX®. J Bone Miner Res. doi: 10.1002/jbmr.1606